The emergence of mephedrone together with other synthetic cathinones has introduced challenges for lawmakers and regulatory businesses tasked with controlling the proliferation of recent psychoactive substances. The dynamic mother nature of artificial drug manufacturing, coupled with the flexibility of chemists to switch molecular constructions to